Adimab is a biotechnology company that provides a discovery platform functioning as a synthetic human immune system. It helps to develop antibody therapeutics across a range of medical conditions, including cancer as well as autoimmune and infectious diseases. The company uses technology that combines discovery, optimization, and bispecific features.